AIN457 300 mg

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Chronic Plaque Type PsoriasisModerate to Severe Chronic Plaque-Type Psoriasis

Phase 3

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

CompletedNCT01640951

Novartis PharmaceuticalsModerate to Severe Chronic Plaque-Type Psoriasis

Start: 2012-09-16End: 2017-05-04Updated: 2018-05-25

Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

CompletedNCT02074982

Novartis PharmaceuticalsChronic Plaque Type Psoriasis

Start: 2014-02-26End: 2016-06-29Updated: 2017-07-21

Related Papers

Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region.

2022-11-053 citations

Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications

Rheumatology and Therapy2022-03-1933 citations

Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis

Dermatology and Therapy2021-12-067 citations

Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.

2019-07-2517 citations

Continued treatment with secukinumab is associated with high retention or regain of response.

2019-07-178 citations

Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis

Journal of Dermatological Treatment2019-07-0954 citations

Secukinumab, a fully human anti‐interleukin‐17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years

Journal of the European Academy of Dermatology and Venereology2019-04-2231 citations

Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study.

2017-09-0447 citations

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.

2015-06-17394 citations